RE:RE:RE:AbsoluteResults of a phase 2 clinical trial. If the midpoint results meet the endpoint goals, they can close the phase 2 trial and start licensing the treatment in Korea and Japan. A typical biotech with a completed phase 2 trial is worth anywhere from 100 M to 300M$ and hem is currently worth 30M$ for a variety of reasons. Just look at whats happened with sernova based on some phase 2 data they just released and they are only midway through their phase 2. Ive been following HEM for 4 years and they have a ton of data proving really high efficacy of their stem cell treatment so the company is very optimistic that the midpoint data will mirror earlier trials. Huge opportunity and worth a look.